Loading...
•
Dec 31, 2025
Wave Life Sciences Q4 2025 Earnings Report
Wave Life Sciences reported lower fourth quarter 2025 revenue and a net loss as research and development expenses increased year-over-year.
Key Takeaways
For Q4 2025, Wave Life Sciences generated revenue of 17244000 and reported a net loss of 53179000, driven by higher research and development and general and administrative expenses compared to the prior year quarter.
Revenue decreased to 17244000 from 83748000 in the prior year quarter.
Net loss was 53179000 compared to net income of 29253000 in Q4 2024.
Research and development expenses increased to 52814000.
Cash and cash equivalents totaled 602068000 at quarter end.
Forward Guidance
The company expects its current cash and cash equivalents of 602068000 as of December 31, 2025 to fund operations into the third quarter of 2028, with multiple clinical data updates and regulatory milestones anticipated in 2026.
Positive Outlook
- Cash runway expected into 3Q 2028.
- Six-month follow-up data from WVE-007 Cohort 2 expected in 1Q 2026.
- Regulatory feedback on WVE-006 accelerated approval pathway anticipated mid-2026.
- Phase 2a multidose portion of INLIGHT planned for 1H 2026.
- Additional WVE-007 trials as incretin add-on and maintenance planned for 2026.
Challenges Ahead
- Significant net loss of 53179000 in Q4 2025.
- Revenue declined substantially year-over-year.
- Increased research and development expenses year-over-year.
- Pipeline advancement subject to regulatory risks.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...